| Literature DB >> 32268584 |
Simona Izzo1, Valeria Naponelli1,2,3, Saverio Bettuzzi1,2,3.
Abstract
Prostate cancer (PCa) is a multifactorial disease with an unclear etiology. Due to its high prevalence, long latency, and slow progression, PCa is an ideal target for chemoprevention strategies. Many research studies have highlighted the positive effects of natural flavonoids on chronic diseases, including PCa. Different classes of dietary flavonoids exhibit anti-oxidative, anti-inflammatory, anti-mutagenic, anti-aging, cardioprotective, anti-viral/bacterial and anti-carcinogenic properties. We overviewed the most recent evidence of the antitumoral effects exerted by dietary flavonoids, with a special focus on their epigenetic action in PCa. Epigenetic alterations have been identified as key initiating events in several kinds of cancer. Many dietary flavonoids have been found to reverse DNA aberrations that promote neoplastic transformation, particularly for PCa. The epigenetic targets of the actions of flavonoids include oncogenes and tumor suppressor genes, indirectly controlled through the regulation of epigenetic enzymes such as DNA methyltransferase (DNMT), histone acetyltransferase (HAT), and histone deacetylase (HDAC). In addition, flavonoids were found capable of restoring miRNA and lncRNA expression that is altered during diseases. The optimization of the use of flavonoids as natural epigenetic modulators for chemoprevention and as a possible treatment of PCa and other kinds of cancers could represent a promising and valid strategy to inhibit carcinogenesis and fight cancer.Entities:
Keywords: apoptosis; cell cycle arrest; chemoprevention; epigenetic regulation; flavonoids; green tea catechins; lncRNAs; miRNAs; natural compounds; prostate cancer
Mesh:
Substances:
Year: 2020 PMID: 32268584 PMCID: PMC7231128 DOI: 10.3390/nu12041010
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717
Figure 1General structure of a flavonoid.
Structure of the main flavonoid compounds. Based on their structural differences, flavonoids can be divided into flavones, flavonols, flavanones, isoflavonoids, flavanols, and anthocyanins. Flavonoids whose epigenetic action is detailed in the text are in bold.
| Chemical Structure | Bonds | Compounds | |
|---|---|---|---|
| FLAVONES |
| Double bond between C2-C3 and a ketone in C4 of the C ring. | Apigenin |
| FLAVONOLS |
| Hydroxylic group, a double bond between C2-C3 and a ketone in C ring. | Quercetin |
| FLAVANONES |
| Lack the double bond between C2-C3 in C ring; only hydroxyl and methoxy groups as substituents. | Silibinin |
| ISOFLAVONOIDS |
| Large diversity of structure in the C ring. The B ring is attached at C3 rather C2 of the C ring. | Genistein |
| FLAVANOLS OR CATECHINS |
| No double bond of C2-C3 in the hydroxyl group in position 3. | EGCG |
| ANTHOCYANINS |
| Flavylium cation binding hydroxyl groups and/or methoxy group(s) in R₁, R₂, and R₃ position. | Delphinidin |
Figure 2Epigenetic mechanisms of flavonoid action. Flavonoids (apigenin, silibinin, catechins) can act as histone deacetylase (HDAC) inhibitors by promoting the transcriptional expression of genes involved in cell cycle arrest and apoptosis induction. Flavonoids (genistein, catechins) promote the downregulation of DNA methyltransferase (DNMT)1 that leads to the demethylation, and consequent reactivation, of methylation-silenced genes.
Targets and cellular mechanism of flavonoids in prostate cancer (PCa). Flavonoids that exert anti-tumoral effect in PCa through epigenetic mechanisms are reported in the table. See text for details.
| Cell Lines/Animal Models/Clinical Trials | Molecular Target | Cellular Mechanism | Ref | ||
|---|---|---|---|---|---|
|
| Apigenin | PC3-22Rv1 cells | ↓ HDAC1, HDAC3 | Cell cycle arrest | [ |
| PC3 xenograft mice | ↓ HDAC1, HDAC3 | Tumor growth reduction | [ | ||
| Luteolin | PC3-LNCaP cells | ↓ miR-301 | Inhibition proliferation | [ | |
| +/- gefitinib | PC3 cells | ↑ miR-603 | Growth arrest | [ | |
| PC3 cells | Binding to H4 | Cell cycle arrest | [ | ||
| Morin | DU145, PC3 cells | ↓ miR-155 | Apoptosis | [ | |
| Tricin | PC3 cells | ↓ miR-21 | Inhibition proliferation | [ | |
|
| Quercetin | PC3 cells | ↓ miR-21 | Apoptosis, cell cycle arrest and reduced invasive capacity | [ |
|
| Silibinin | DU145, PC3 cells | ↓ EZH2, ↑ DNMT | Cell cycle arrest | [ |
|
| Genistein | LNCaP, LAPC-4 cells | ↓ DNMT1, DNMT3b | Inhibition proliferation | [ |
| PC3, DU145 cells | ↑ miR-34a, ↓ HOTAIR | Cell cycle arrest | [ | ||
|
| EGCG | PC3 cells | ↓ DNMT | Cell growth inhibition | [ |
| EGCG | LNCaP cells | ↓ HAT | Cell growth inhibition | [ | |
| EGCG | LNCaP 22Rv1 cells | ↓ AR | Cell growth inhibition | [ | |
| Polyphenon E | LNCaP, PC3 cells | ↓ HDAC1, HDAC2, HDAC3, HDAC8 | Cell cycle arrest | [ | |
| Polyphenon E | LNCaP cells | ↓ DNMT1 | Growth arrest | [ | |
| Polyphenon E/EGCG | DUPRO, LNCaP cells | ↓ HDAC1, EZH2 | Migration, invasion abrogation | [ | |
|
| Delphinidin | LNCaP cell lines | ↓ HDAC3 | apoptosis | [ |
Histone deacetylase (HDAC), Enhancer of zeste homolog 2 (EZH2), histone acetyl transferase (HAT), DNA methyltransferase (DNMT), androgen receptor (AR), histone 3, 4 (H3, H4), HOX Transcript Antisense RNA (HOTAIR).